Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030

With changing lifestyle and subsequently rising numbers of chronic ailments (such as obesity and diabetes), the prevalence of fibrotic diseases has also witnessed a surge globally. For instance, liver fibrosis is a common secondary pathological development observed in patients suffering from metabolic / cholestatic diseases, individuals consuming excessive quantities of alcohol and patients suffering from viral hepatitis. With non-alcoholic fatty liver disease (NAFLD) (subsequently progressing to nonalcoholic steatohepatitis / NASH) being the primary cause of liver disease, nearly 4.5 million adults in the US have been diagnosed with this condition in 2018. Similarly, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening interstitial lung disease reported in individuals with high exposure to deadly pollutants, radiation treatments and chemotherapeutic drugs. Although, IPF is a rare disease, nearly 40,000 new cases are diagnosed in the Europe, annually. Early diagnosis of fibrotic diseases is crucial to the condition being successfully managed / treated. However, timely diagnosis of this medical condition has been a known challenge due to the absence of overt symptoms. When symptoms appear, the patient suspected with the disease is suggested to undergo tissue biopsy for the disease confirmation. Considering that a tissue biopsy, a painful and traumatic procedure, is the currently accepted standard of diagnosis, there is a stigma associated with the process. Moreover, owing to the invasive nature of the test, it cannot be frequently repeated in order to monitor disease progress or validate therapeutic outcomes. There is, therefore, an established unmet need for a safer and more patient friendly diagnostic method.

Leave a Reply